Nanoparticle Contract Manufacturing (Focus on Lipid and Metal Nanoparticles) Market by Company Size (Very Small, Small, Mid-sized and Large), Type of Nanoparticle(s) Manufactured (Lipid and Metal Nanoparticles), Scale of Operation (Preclinical, Clinical

Nanoparticle Contract Manufacturing (Focus on Lipid and Metal Nanoparticles) Market by Company Size (Very Small, Small, Mid-sized and Large), Type of Nanoparticle(s) Manufactured (Lipid and Metal Nanoparticles), Scale of Operation (Preclinical, Clinical and Commercial), Type of End User (Educational Institutions, Pharmaceutical Companies, Research Institutions, and Other End Users), and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2021-2035

Over the past few decades, the pharmaceutical industry has witnessed significant growth, as also evident from the continuously growing pipeline of drug candidates that have been marketed or are being evaluated across several development stages. However, a recent study published in the journal of Analytical and Pharmaceutical Research has highlighted that around 90% of the candidates in the current preclinical development pipeline and more than 40% of the marketed pharmacological products are associated with concerns related to solubility / permeability. Further, it was observed that a pharmacological product became 10% less vigorous, each time, when mixed with another product, due to drug incompatibility. Therefore, players engaged in this domain are actively trying to identify ways to improve / augment physiochemical properties and drug-like behavior of pharmacological products. Amidst other alternatives, the use of nanoparticles has garnered the attention of many drug developers. In fact, the novel vaccines developed to treat COVID-19 are enclosed within a layer of lipid nanoparticles; these molecules assist the delivery of active ingredients to the required site of action. Moreover, many drug developers are using lipid / metal nanoparticles to re-formulate existing product candidates in order to further improve their bioavailability / biocompatibility. However, for some of the nanoparticles having medical applications, the associated manufacturing processes are highly complex, capital-intensive and fraught with multiple challenges, such as need for specialized expertise (especially in case of lipid nanoparticles), lack of facilities with necessary infrastructure, as well as concerns related to storage and stability. , Considering the routine operations-related and technical challenges, an increased number of pharmaceutical companies have demonstrated the preferences to outsource their respective nanoparticle production operations to specialized service providers.

There are numerous benefits of engaging contract development and manufacturing (CDMO) / contract manufacturing organizations (CMO) for nanoparticle manufacturing; for instance, contracting a supplier for medical grade nanoparticles enables sponsors to leverage new technologies (available with the service provider), access larger capacities and achieve greater operational flexibility. Presently, there are several contract manufacturers and technology providers, who claim to have the required capabilities to manufacture nanoparticles (lipid and metal nanoparticles). However, the global expertise and capabilities necessary for the production of GMP grade nanoparticles are currently limited. As a result, many companies offering contract manufacturing services for nanoparticles are actively trying to consolidate their presence in this field, by entering into various strategic alliances to broaden their respective service portfolios. It is also worth highlight that, recently, a number of deals were inked between vaccine developers and CMOs in order to cater the urgent need for nanoparticle-based solutions for the development of COVID-19 vaccines. Given the benefits of using nanoparticles to improve drug-like properties, we believe, that the demand for high quality nanoparticles is likely to drive considerable growth within the specialty contract manufacturing market in the coming years.

The “Nanoparticles Contract Manufacturing (Focus on Lipid and Metal Nanoparticles) Market by Company Size (Very Small Companies, Small Companies, Mid-Sized Companies, and Large Companies), Type of Nanoparticle(s) Manufactured (Lipid and Metal Nanoparticles), Scale of Operation (Preclinical, Clinical, and Commercial), Type of End User (Educational Institutions, Pharmaceutical Companies, Research Institutions, and Other End Users), and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa (MENA), Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2021-2035” report features an extensive study of contract service providers engaged in manufacturing of nanoparticles for the purpose of preclinical development, clinical research and commercialization. The study features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this domain. Amongst other elements, the report features:

 A detailed overview of the current market landscape of nanoparticle contract manufacturers, along with information on several relevant parameters, such as year of establishment, company size (very small, small, mid-sized and large), location of headquarters, type of organization (CDMO and CMO), type of nanoparticle(s) manufactured (lipid and metal nanoparticles), location and number of manufacturing facilities, scale of operation (preclinical, clinical, and commercial), type of end user (educational institutions, pharmaceutical companies. research institutions, and other end users), type of service(s) offered, quality certifications and regulatory bodies.
 An in-depth analysis, highlighting the contemporary market trends using six schematic representations, including [A] a comparative world map representation, based on company size, location of the headquarters and type of nanoparticle(s) manufactured, [B] a bubble representation based on company size and type of organization, [C] a stacked bar chart representation based on company size and scale of operation, [D] a heat map representation highlighting the regional distribution of developers engaged in this domain, [E] a 4D bubble analysis comparing the leading players engaged in this domain, based on several relevant parameters (such as company size, type of nanoparticle(s) manufactured, number of manufacturing facilities, and number of service(s) offered), [F] a grid representation illustrating the distribution of nanoparticle contract manufacturers based several relevant parameters (such as type of organization, type of nanoparticle(s) manufactured, scale of operation, type of end user, and type of service(s) offered).
 An in-depth company competitiveness analysis of nanoparticle contract manufacturers, based on several relevant parameters, such as company’s service strength (taking into consideration years of experience, type of organization, type of nanoparticle(s) manufactured, number of manufacturing facilities, scale of operation, type of end user and type of service(s) offered) and partnership strength (taking into consideration the number of partnerships and type of agreement).
 Elaborate profiles of key players that offer contract manufacturing services for nanoparticle(s). Each profile features a brief overview of the company, along with information on year of establishment, location of headquarters, number of employees, key executives, recent developments and an informed future outlook.
 An analysis of recent partnerships inked between various stakeholders engaged in this domain, during the period 2015-2021, based on several relevant parameters, such as year of partnership, type of partnership (company acquisitions, manufacturing agreements, mergers, product development agreements, product distribution agreements, technology integration agreements, and other agreements), type of partner, type of nanoparticle(s) manufactured, emerging focus area, seniority level of stakeholders, most active players (in terms of number of partnerships), type of agreement and regional distribution.
 An insightful analysis, highlighting the various factors that need to be taken into consideration by nanoparticle(s) developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO. Further, the analysis highlights all the key parameters that must be considered by players based on company sizes (very small, small, mid-sized, and large), while taking the aforementioned decision.

One of the key objectives of the report was to evaluate the current opportunity and the future potential of the nanoparticle contract manufacturing market over the next fourteen years. We have also provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, over the period 2021-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] company size (very small, small mid-sized, and large), [B] type of nanoparticle(s) manufactured (lipid and metal nanoparticles), [C] scale of operation (preclinical, clinical and commercial) and [D] type of end user (educational institutions, pharmaceutical companies, research institutions, and other end users), and [E] key geographical regions (North America, Europe, Asia, MENA, Latin America and rest of the world). In order to account for future uncertainties in the market and add robustness to our forecast model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market’s evolution. The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views

While the focus has been on forecasting the market over the coming 9 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED
 Who are the key players involved in nanoparticle contract manufacturing?
 Which global regions are considered as key hubs for contract manufacturing of nanoparticles?
 What are the most common services offered by nanoparticle contract manufacturers?
 What type of partnership models are commonly adopted by stakeholders engaged in this industry?
 Which factors are likely to influence the decision of nanoparticle manufacturing being done in-house or outsourced?
 How is the current and future market opportunity likely to be distributed across key market segments?

CHAPTER OUTLINES

Chapter 2 is an executive summary of key insights captured during our research. It offers a high-level view on the likely evolution of the nanoparticle contract manufacturing market in the short to mid-term, and long term.

Chapter 3 provides a general introduction on nanoparticles, along with information on various types and applications of nanoparticles in the pharmaceutical industry. Additionally, it includes information on the various challenges associated with manufacturing of nanoparticles. Further, it features a brief discussion on the growing need for outsourcing within this domain.

Chapter 4 provides a detailed review of the overall landscape of nanoparticle contract manufacturing landscape. It includes information of over 50 contract manufacturers currently engaged in the domain of nanoparticle contract manufacturing. Additionally, it features an in-depth analysis of service providers, based on several relevant parameters, such as year of establishment, company size (very small, small, mid-sized and large), location of headquarters (region-wise), type of organization (CDMO and CMO), type of nanoparticle(s) manufactured (lipid and metal nanoparticles), location and number of nanoparticle manufacturing facilities, scale of operation (preclinical, clinical and commercial), type of end user (educational institutions, pharmaceutical companies, research institutions and other end users), quality certifications, regulatory organizations and include details on type of services offered (analytical method development, fill / finish and packaging, formulation development, manufacturing, method qualification and sustainability, process development / pre-formulation, scale-up, stability studies, and other services).

Chapter 5 highlights the contemporary market trends in six schematic representations, which include [A] a comparative world map representation, based on company size, location of the headquarters and type of nanoparticle(s) manufactured, [B] a bubble representation based on company size and type of organization, [C] a stacked bar chart representation based on company size and scale of operation, [D] a heat map representation highlighting the regional distribution of developers engaged in this domain, [E] a 4D bubble analysis comparing the leading players engaged in this domain, based on several relevant parameters (such as company size, type of nanoparticle(s) manufactured, number of manufacturing facilities, and number of services offered,), [F] a grid representation illustrating the distribution of nanoparticle contract manufacturers based several relevant parameters (such as type of organization, type of nanoparticle(s) manufactured, scale of operation, type of end user, and types of service(s) offered).

Chapter 6 features a detailed company competitiveness analysis of the nanoparticle contract manufacturers, of very small, small, mid-sized and large companies, based on several relevant parameters, such as company’s service strength (taking into consideration a number of parameters, such as years of experience, type of organization, type of nanoparticle(s) manufactured, number of manufacturing facilities, scale of operation, type of end user and types of service(s) offered) and partnership strength (taking into consideration the number of partnerships and type of agreement).

Chapter 7 provides detailed profiles of the key players (shortlisted based on a proprietary criterion) that are active in the nanoparticle contract manufacturing market. Each profile provides an overview of the company, along with information on year of establishment, location of headquarters, number of employees, key executives, details on recent developments, as well as an informed future outlook.

Chapter 8 features an analysis of recent collaborations and partnerships that have been inked between several stakeholders engaged in this domain, during the period 2015-2021. It includes a brief description of the partnership models (including company acquisitions, manufacturing agreements, mergers, product development agreements, product distribution agreements, technology integration agreements, and other agreements) adopted by various stakeholders in the domain of nanoparticle contract manufacturing. Further, it comprises of analysis based on the year of partnership, type of partner, type of nanoparticle(s) manufactured, emerging focus area, seniority level of stakeholders, most active players (in terms of number of partnerships), type of agreement. Further, the chapter includes a world map representation of all the deals inked in this field in the period 2015-2021, highlighting both intercontinental and intracontinental partnership activity.

Chapter 9 presents an insightful analysis that highlights the various factors that need to be taken into consideration by nanoparticle-based therapeutics developers, while deciding whether to manufacture their respective therapeutics in-house or engage the services of a CMOs. Further, the analysis highlights all the key parameters that must be considered by players of different company sizes (very small, small, mid-sized, and large) while taking the aforementioned decision.

Chapter 10 features a comprehensive market forecast analysis, highlighting the likely growth of the nanoparticle contract manufacturing market, for the period 2021-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] company size (very small, small mid-sized, and large), [B] type of nanoparticle(s) manufactured (lipid and metal nanoparticles), [C] scale of operation (preclinical, clinical and commercial) and [D] type of end user (educational institutions, pharmaceutical companies, research institutions, and other end users), and [E] key geographical regions (North America, Europe, Asia, MENA, Latin America and rest of the world).

Chapter 11 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 12 provides the transcripts of interviews conducted with representatives from renowned organizations, which are engaged in the domain of nanoparticle contract manufacturing. In this chapter, we have presented the details of our conversation with Asha Van Rooijen and Bart Metselaar (Founder and Chief Executive Officer, Director, Research and Development, LIPOSOMA).

Chapter 13 is an appendix, that provides tabulated data and numbers for all the figures included in the report.

Chapter 14 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS
The following companies and organizations have been mentioned in the report.

1. Ajinomoto Bio-Pharma Services
2. Alfa Aesar
3. Amplicon Biotech
4. Applied Chemical Works
5. Arcturus Therapeutics
6. Ardena
7. Ascendia Pharmaceuticals
8. AstraZeneca
9. AVANSA Technology & Services
10. Avanti Polar Lipids
11. Axolabs
12. BASF
13. BBI Group
14. BioNTech
15. BIOZOL Diagnostica
16. BOC Sciences
17. Caisson Biotech
18. Cal Nano
19. Cambridge Nanomaterials Technology
20. CanSinoBIO
21. Cayman Chemical
22. CONTRACTOR BUSINESS CENTER
23. Celonic
24. Center for Applied Nanotechnology
25. Cerion
26. ChemConnection
27. CliniSciences
28. CordenPharma
29. Creative Biolabs
30. Croda
31. Crystallics
32. CureVac
33. Curia
34. CYBERNANO
35. Cytodiagnostics
36. Daiichi Sankyo
37. Danaher
38. DCN Dx
39. Deakin University
40. Dolomite Microfluidics
41. E.M. Sullivan Associates
42. Eikonix
43. EMJapan
44. Encapsula NanoSciences
45. Entos
46. European Commission
47. Evonik
48. Exelead
49. Fortis Life Sciences
50. FUJIFILM Holdings
51. GHO Capital
52. Howei Pharm
53. Hongwu International Group
54. i-DNA Biotechnology
55. Idifarma
56. Integrity Bio
57. Larodan
58. LEON
59. LIPOSOMA
60. LSNE Contract Manufacturing
61. Meliorum Technologies
62. Molchem Technologies UK
63. MyBiotech
64. Nagase Medicals
65. Nanochemazone
66. nanoComposix
67. Nanocs
68. NanoHybrids
69. NanoMaterials Technology
70. Nanomics Technologies
71. Nanophase Technologies
72. Nanoshel
73. Nanostructured & Amorphous Materials
74. NARD Institute
75. NNCrystal
76. Novo Holdings
77. Nucleus Medical Media
78. NVIGEN
79. NYACOL® Nano Technologies
80. Ocean NanoTech
81. Osaka University
82. Permira
83. Pfizer
84. Pharmavize
85. Phosphorex
86. Polymun
87. Precision NanoSystems
88. Pró-Análise
89. Prodotti Gianni
90. Santhiram Chemicals
91. Seashell Technology
92. Shionogi
93. Sirnaomics
94. SkySpring Nanomaterials
95. Stanipharm
96. Stratech Scientific
97. Strem
98. Syntagon
99. T&T Scientific
100. TechNanoIndia
101. The Energy and Resources Institute (TERI)
102. U.S. Army
103. Vaxinano
104. Veritas Technologies
105. ZoneOne Pharma

Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.